Danaher Corporation: Takeaways from DHR dinner & fireside chat at 2026 BofA Healthcare Conference

Research evidence excerpt

Danaher Corporation: Takeaways from DHR dinner & fireside chat at 2026 BofA Healthcare Conference

malizing as China resets

Mgmt. pushed back on the view that the emerging markets growth model is structurally

impaired, framing the current dynamic as a China-led reset rather than broader emerging

markets (EM) slowdown. China remains a near-term drag, but performance is tracking as

expected, with VBP pricing headwinds becoming less severe and patient volume

normalization already underway. Over time, this supports a recovery to ~5–10% growth

off a depressed base, without requiring a return to historical double-digit levels. At the

same time, growth is broadening across other high-growth regions (Southeast Asia,

India, Saudi Arabia), where the company is gaining traction in core diagnostics and

biopharma services, supported by increasing healthcare investment and local

manufacturing buildouts. With China now closer to ~10% of revenue (vs. peak ~15%),

the EM framework is normalizing toward a more balanced contribution — with

developed markets at +Mid-Single Digit growth and EM modestly above that, even with

a lower China contribution.

Price objective basis & risk

Danaher Corporation (DHR)

Our $270 price objective (PO) is based on a discounted cash flow (DCF) analysis

(assumes 8.5% weighted-average cost of capital-WACC, 4% terminal growth rate). We

believe this discount rate is appropriate as several key acquisitions (e.g., GE Life

Sciences, Aldevron, Cepheid) have significantly accelerated Danaher's organic revenue

growth, enhanced margins, lowered the company's cyclical exposure, and increased the

percentage of sales from recurring revenues.

Downside risks to our PO are F/X risks, economic & macro risks, cyclical exposure,